NRX Pharmaceuticals Inc (NRXP NASDAQ) stock market data APIs
$2.99
-0.23(-7.1%)
as of January 24, 2025
NRX Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Prev. Close
3.22
Open
2.99
Volume
645 K
High
3.32
Low
2.92
52 wk Range
1.1-7.33
Market Cap
38 943 K
Shares Outstanding
12 094 K
Revenue
0
EPS
-0.15
Beta
1.271
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NRX Pharmaceuticals Inc data using free add-ons & libraries
Get NRX Pharmaceuticals Inc Fundamental Data
NRX Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -23 257 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-11
- EPS/Forecast: -0.64
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NRX Pharmaceuticals Inc News
New
11 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can ...
NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased NRx Pharmaceuticals Inc. (f/k/a Big Rock Part...
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm
PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx”) on behalf of the company’s long-term shareho...
NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger
NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased NRx Pharmaceuticals Inc. (f/k/a Big Rock Part...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
